-
Je něco špatně v tomto záznamu ?
The advantages and limitations of impedance aggregometry in detection of heparin-induced thrombocytopenia
L Slavik, G Svobodova, J Ulehlova, V Krcova, A Hlusi, J Prochazkova, M Kaletova, Y Hrckova, K Indrak
Jazyk angličtina Země Německo
Grantová podpora
NT14394
MZ0
CEP - Centrální evidence projektů
PubMed
25185417
Knihovny.cz E-zdroje
- MeSH
- agregace trombocytů * účinky léků MeSH
- elektrická impedance MeSH
- ELISA MeSH
- heparin * chemie škodlivé účinky MeSH
- imunoglobulin G chemie MeSH
- lidé MeSH
- pravděpodobnost MeSH
- reprodukovatelnost výsledků MeSH
- senioři MeSH
- senzitivita a specificita MeSH
- statická elektřina MeSH
- trombocytopenie * chemicky indukované MeSH
- trombocyty MeSH
- vyšetření funkce trombocytů MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
BACKGROUND: Heparin-induced thrombocytopenia (HIT) represents a serious complication of heparin treatment. IgG antibodies binding platelet factor 4 (PF4) and heparin trigger the clinical manifestations of HIT. However, only a portion of the antibodies have the ability to activate platelets, and these can be identified by a platelet aggregation test (functional testing). Current methods HIPA and SRA are time-consuming and difficult if HIT is clinically suspected; therefore, numerous new methods have recently been developed. METHODS: To determine HIT, impedance aggregometry using the Multiplate analyzer (MEA) as heparin-induced aggregation techniques and the Technozym HIT Ig ELISA test were used. The MEA method uses sensitization of donor platelets with patient plasma in the presence of heparin at a concentration of 0.5 IU/mL. The results were compared with the ELISA test. RESULTS: We examined 190 patients at clinically intermediate and higher risk of HIT according to the 4T score. All samples were examined by the ELISA test and MEA, with positive samples being further confirmed by high-concentration heparin. The methodology was modified with respect to the dilution for high positive samples and assessment has been extended to an index of inhibition. CONCLUSIONS: In the studied group, we demonstrated that MEA has sufficient sensitivity and higher specificity. In the group of patients, 10.0% showed positive results by MEA as compared with 7.3% determined by ELISA. Unlike the ELISA methods of the same quality, MEA is more suitable for detecting platelet-activating HIT antibodies in practice.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18034623
- 003
- CZ-PrNML
- 005
- 20190104103845.0
- 007
- ta
- 008
- 181011s2014 gw f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)25185417
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Slavík, Luděk $7 xx0081908 $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
- 245 14
- $a The advantages and limitations of impedance aggregometry in detection of heparin-induced thrombocytopenia / $c L Slavik, G Svobodova, J Ulehlova, V Krcova, A Hlusi, J Prochazkova, M Kaletova, Y Hrckova, K Indrak
- 520 9_
- $a BACKGROUND: Heparin-induced thrombocytopenia (HIT) represents a serious complication of heparin treatment. IgG antibodies binding platelet factor 4 (PF4) and heparin trigger the clinical manifestations of HIT. However, only a portion of the antibodies have the ability to activate platelets, and these can be identified by a platelet aggregation test (functional testing). Current methods HIPA and SRA are time-consuming and difficult if HIT is clinically suspected; therefore, numerous new methods have recently been developed. METHODS: To determine HIT, impedance aggregometry using the Multiplate analyzer (MEA) as heparin-induced aggregation techniques and the Technozym HIT Ig ELISA test were used. The MEA method uses sensitization of donor platelets with patient plasma in the presence of heparin at a concentration of 0.5 IU/mL. The results were compared with the ELISA test. RESULTS: We examined 190 patients at clinically intermediate and higher risk of HIT according to the 4T score. All samples were examined by the ELISA test and MEA, with positive samples being further confirmed by high-concentration heparin. The methodology was modified with respect to the dilution for high positive samples and assessment has been extended to an index of inhibition. CONCLUSIONS: In the studied group, we demonstrated that MEA has sufficient sensitivity and higher specificity. In the group of patients, 10.0% showed positive results by MEA as compared with 7.3% determined by ELISA. Unlike the ELISA methods of the same quality, MEA is more suitable for detecting platelet-activating HIT antibodies in practice.
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a senioři $7 D000368
- 650 02
- $a trombocyty $7 D001792
- 650 02
- $a elektrická impedance $7 D017097
- 650 02
- $a ELISA $7 D004797
- 650 02
- $a ženské pohlaví $7 D005260
- 650 12
- $a heparin $x chemie $x škodlivé účinky $7 D006493
- 650 02
- $a lidé $7 D006801
- 650 02
- $a imunoglobulin G $x chemie $7 D007074
- 650 02
- $a mužské pohlaví $7 D008297
- 650 02
- $a Middle Aged
- 650 12
- $a agregace trombocytů $x účinky léků $7 D010974
- 650 02
- $a vyšetření funkce trombocytů $7 D010979
- 650 02
- $a pravděpodobnost $7 D011336
- 650 02
- $a reprodukovatelnost výsledků $7 D015203
- 650 02
- $a senzitivita a specificita $7 D012680
- 650 02
- $a statická elektřina $7 D055672
- 650 12
- $a trombocytopenie $x chemicky indukované $7 D013921
- 700 1_
- $a Svobodová, Gabriela, $d 1988- $7 xx0224773 $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
- 700 1_
- $a Úlehlová, Jana $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic $7 xx0117725
- 700 1_
- $a Krčová, Věra, $d 1934- $7 nlk19990073440 $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
- 700 1_
- $a Hluší, Antonín $7 xx0074065 $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
- 700 1_
- $a Procházková, Jana $7 xx0067433 $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
- 700 1_
- $a Kaletová, Markéta $7 xx0097230 $u Department of Internal Medocine 1 - Cardiology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
- 700 1_
- $a Hrčková, Yvona $7 xx0076929 $u Department of Internal Medocine 1 - Cardiology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
- 700 1_
- $a Indrák, Karel, $d 1947- $7 jn20000401162 $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
- 773 0_
- $t Clinical Laboratory $x 1433-6510 $g Roč. 60, č. 8 (2014), s. 1319-1324 $p Clin Lab $w MED00009480
- 773 0_
- $p Clin Lab $g 60(8):1319-24, 2014 $x 1433-6510
- 910 __
- $a ABA008 $y 4 $z 0
- 990 __
- $a 20181011145941 $b ABA008
- 991 __
- $a 20190104104040 $b ABA008
- 999 __
- $a ok $b bmc $g 1341477 $s 1031620
- BAS __
- $a 3
- BMC __
- $a 2014 $b 60 $c 8 $d 1319-1324 $x MED00009480 $i 1433-6510 $m Clinical laboratory
- GRA __
- $a NT14394 $p MZ0
- LZP __
- $a NLK 2018/lp